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ARTICLE OPEN
A functional genomic screen in vivo identiﬁes CEACAM5 as a
clinically relevant driver of breast cancer metastasis
Emily Powell1, Jiansu Shao1, Hector M. Picon1, Christopher Bristow2, Zhongqi Ge1,3,4, Michael Peoples2, Frederick Robinson2,
Sabrina L. Jeter-Jones1, Christopher Schlosberg5, Caitlin L. Grzeskowiak6, Fei Yang7, Yun Wu8, Ignacio Wistuba7, Stacy L. Moulder9,
William F. Symmans8, Kenneth L. Scott6, John R. Edwards5, Han Liang3,4, Timothy P. Heffernan2 and Helen Piwnica-Worms1
Tumor cells disseminate early in tumor development making metastasis-prevention strategies difﬁcult. Identifying proteins that
promote the outgrowth of disseminated tumor cells may provide opportunities for novel therapeutic strategies. Despite multiple
studies demonstrating that the mesenchymal-to-epithelial transition (MET) is critical for metastatic colonization, key regulators that
initiate this transition remain unknown. We serially passaged lung metastases from a primary triple negative breast cancer
xenograft to the mammary fat pads of recipient mice to enrich for gene expression changes that drive metastasis. An unbiased
transcriptomic signature of potential metastatic drivers was generated, and a high throughput gain-of-function screen was
performed in vivo to validate candidates. Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) was identiﬁed as
a metastatic driver. CEACAM5 overproduction enriched for an epithelial gene expression pattern and facilitated tumor outgrowth at
metastatic sites. Tissues from patients with metastatic breast cancer conﬁrmed elevated levels of CEACAM5 in lung metastases
relative to breast tumors, and an inverse correlation between CEACAM5 and the mesenchymal marker vimentin was demonstrated.
Thus, CEACAM5 facilitates tumor outgrowth at metastatic sites by promoting MET, warranting its investigation as a therapeutic
target and biomarker of aggressiveness in breast cancer.
npj Breast Cancer  (2018) 4:9 ; doi:10.1038/s41523-018-0062-x
INTRODUCTION
Metastatic breast cancer is incurable in most cases.1 Triple
negative breast cancer (TNBC) is an aggressive subtype of breast
cancer that is characterized by high rates of metastasis and poor
prognosis.2,3 TNBC preferentially metastasizes to visceral organs
including lungs.2 Metastasis is a multistep process that includes
escape from the primary tumor, survival in the blood circulation,
extravasation, and tumor outgrowth in the metastatic site.4
Successful completion of each of these steps is essential for the
formation of macroscopic metastatic disease. The development of
novel strategies to prevent or treat metastatic TNBC will rely on
deﬁning properties of the tumor cell as well as the metastatic
niche that enable dissemination, seeding, and outgrowth of
metastatic tumor cells.5,6
Previous studies identiﬁed gene expression changes in meta-
static subpopulations of breast cancer cells,7–10 and in some cases
these gene expression changes predicted patient survival.9,11,12
Unbiased genetic screens are useful for simultaneously identifying
and functionalizing metastatic drivers as well as suppressors. In
vivo screening approaches including those that utilize shRNAs or
CRISPR technology have been useful for identifying genes that
suppress metastasis.13 However, metastasis suppressors are
generally not candidate therapeutic targets. Gain-of-function
forward genetic screens in orthotopically-engrafted cancer cell
lines have identiﬁed a limited number of metastasis drivers.14,15
However, successful translation of these collective ﬁndings into
the clinical setting has been limited.16 Furthermore, discordance
between in vitro and in vivo screens has been reported,
highlighting the importance of in vivo model systems.17
Orthotopic patient-derived xenograft (PDX) models are powerful
tools for identifying metastatic drivers because the tumors retain
much of the genomic heterogeneity of the original patient tumor
and require metastatic cells to dynamically regulate gene
expression programs as they metastasize in vivo.18
Epithelial-to-mesenchymal transition (EMT) and its reverse
process mesenchymal-to-epithelial transition (MET) are dynamic
developmental programs that contribute to metastasis.19,20
Epithelial cells undergoing EMT down regulate expression of cell
adhesion molecules, lose adhesive contacts with neighboring
cells, and acquire an invasive migratory phenotype. Thus, EMT
endows cells with the ability to escape the primary tumor, enter
into the hematogeneous and lymphatic circulatory systems,
extravasate, and invade the metastatic site. However, cells that
have undergone EMT exhibit decreased rates of proliferation, and
thus are not well equipped to populate the metastatic site.19
Therefore, upregulation of genes that promote MET may endow
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tumor cells with a selective advantage at the metastatic site.
Despite ﬁndings from multiple studies that MET is critical for
metastatic colonization,19,21,22 the key regulators that initiate the
transition from the mesenchymal to the epithelial cellular state at
the metastatic site remain largely unknown. These regulators may
serve as clinical biomarkers for the aggressiveness of metastatic
lesions that have already colonized the metastatic site. Indeed,
numerous studies have revealed that tumor cells disseminate to
metastatic sites early in tumor progression,23–25 and thus
metastasis-prevention strategies may not be clinically feasible.
Therefore, focusing preclinical efforts on characterizing and
targeting tumor cells that have already seeded the secondary
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site may be a promising clinical intervention for patients with
metastatic TNBC. Here, a functional genomic screen, performed
in vivo using a PDX model derived from the primary breast tumor
of a patient with metastatic TNBC, identiﬁed CEACAM5 as a
metastatic driver, and functional studies demonstrated a role for
CEACAM5 in late-stage metastasis.
RESULTS
Serial passaging of lung metastases in vivo enriches for metastatic
potential
The PDX line WU-BC3 was generated by engrafting breast tumor
cells from a patient with metastatic TNBC into the humanized
mammary fat pads (MFPs) of NOD/SCID mice mice.26,27 We
engineered these tumor cells to stably express Click Beetle Red
Luciferase (CBR-Luc), mCherry, and an shRNA speciﬁc for p53
(shA2) to create the PDX line BC3_A2 (formerly known as BC3-
p53KD28) (Supplementary Fig. 1a). We demonstrated that tumor
cells metastasized from MFPs to physiologically relevant sites
including lung, liver, bone, brain, and lymph nodes.28 Lung
metastases (P0) were isolated from replicate mice, pooled, and
engrafted into the MFPs of recipient mice. The resulting lung
metastases (P1) were isolated, pooled, and engrafted into the
MFPs of additional mice. The lung metastases from these mice
(P2) were also collected and pooled (Supplementary Fig. 1b). We
performed bioluminescence imaging (BLI) of lungs, bones, and
livers at necropsy to quantify the relative magnitude of metastasis
at each passage (Supplementary Fig. 1c). Serial passaging enriched
for tumor cells with increased capacity to metastasize to all sites
(Supplementary Fig. 1d–f, h) and required mice to be euthanized
sooner (Supplementary Fig. 1i). By contrast, serial passaging
tumors between MFPs did not result in increased lung metastasis
(Supplementary Fig. 1g), indicating that acquisition of enhanced
metastatic capacity was not simply a consequence of serially
passaging tumors in vivo. Furthermore, tumor cells with enhanced
metastatic capacity did not exhibit a signiﬁcant increase in growth
properties when isolated from MFPs and placed back into the
MFPs of recipient mice (Supplementary Fig. 1j). Taken together,
these results demonstrate that serial passaging of tumor cells from
lungs to MFPs in this model enriches for metastatic potential but
not organ-speciﬁc homing.
Mesenchymal gene expression is reduced in lung metastases
relative to MFP tumors
To identify changes in gene expression patterns that accompany
metastasis, we performed RNA sequencing (RNAseq) on lung
metastases (P0 and P2) and MFP (P0 and P2) tumors (Fig. 1a and
Supplementary Table 1). After subtracting RNAseq reads mapping
to the mouse transcriptome, only human transcript reads were
used for downstream analyses. Principal component analysis (PCA)
revealed decreased discordance among biological replicates with
repeated passaging in vivo, as biological replicates of P2 tumor
samples clustered more closely with each other than with other
subpopulations analyzed (Fig. 1b). Gene Set Enrichment Analysis
(GSEA) revealed that EMT was the most signiﬁcantly down-
regulated pathway in both P0 and P2 lung metastases relative to
MFP tumors (Fig. 1c). TGF-β signaling, which regulates EMT, was
also signiﬁcantly down-regulated in both P0 and P2 lung
metastases (Fig. 1c).
Quantitative real time (qRT-PCR) was performed to monitor
expression of vimentin, a mesenchymal marker, in MFP tumors
and lung metastases throughout serial passaging. Vimentin
expression exhibited a dynamic pattern with higher expression
in MFP tumors relative to corresponding lung metastases at each
passage (Fig. 1d) and to liver metastases at P0 (Supplementary Fig.
2a). Vimentin protein levels recapitulated this dynamic pattern
(Fig. 1e). Additional EMT genes were also downregulated in lung
metastases relative to corresponding MFP tumors (Fig. 1f).
Expression of the mesenchymal marker CDH2 (the gene encoding
N-cadherin) followed the same pattern as vimentin (Supplemen-
tary Fig. 2b), whereas expression of the epithelial marker CDH1
(the gene encoding E-cadherin) exhibited an inverse trend
(Supplementary Fig. 2c). Co-engrafted human stromal ﬁbroblasts
were cleared by the time of tumor harvest (Supplementary Fig.
3a–f), ruling out the possibility that they contributed to the
expression of mesenchymal markers in MFP tumors. Taken
together, these results demonstrate that tumors downregulate
expression of mesenchymal genes once established in metastatic
sites.
Determination of library complexity for high throughput gain of
function screen
A high throughput gain-of-function (GOF) screen was designed to
identify functional drivers of metastasis from our P2 lung
metastases signature. HOXA1, a known driver of metastasis,29
served as a positive control for screen optimization, and GFP was
used as a negative control. BC3_A2 cells were transduced with
lentivirus encoding either HOXA1 or GFP, and infected tumor cells
were mixed in different ratios (Supplementary Fig. 4a). Mixed
populations of tumor cells were then engrafted into the MFPs of
recipient mice, and BLI was used to score lung metastases at the
time of necropsy (Supplementary Fig. 4b). In a second set of
experiments, the metastatic driver ID19 was used in combination
with GFP, but in this case mixed populations of tumor cells were
injected into the tail vein of recipient mice to model the ﬁnal
stages of metastasis (Supplementary Fig. 4c). A signiﬁcant increase
in photon ﬂux was observed from tumors with a HOXA1: GFP or
ID1: GFP ratio of 1:10. These complexity tests demonstrated that a
bona ﬁde metastasis driver could be detected in our screen if
pooled with 9 non-driver open reading frames (ORFs), but a pool
of one driver with 19 non-drivers masked our ability to detect the
driver. Based on these results we limited our pool size to 12 ORFs.
High throughput gain-of-function screening in vivo identiﬁes
candidate functional drivers of TNBC metastasis
To determine which of the upregulated genes from the P2 lung
metastasis signature were capable of driving lung metastasis, we
designed custom barcoded lentiviral libraries encoding the ORFs
Fig. 1 PDX lung metastasis signatures identify genes de-regulated in metastases. a Schematic representation of MPF tumors and lungs
metastases isolated for RNAseq. b Principal component analyses (PCAs) from RNAseq data generated from MFP tumors and lung metastases
used in this study. Each data point represents one sample from an individual mouse. c GSEA pathway analysis on the enriched lung metastasis
signature (P2); the top 5 down (blue)- and up (red)regulated processes are shown. NES, normalized enrichment score. Boxes indicate FDR <0.1
for statistical signiﬁcance. Enrichment plots for epithelial mesenchymal transition (EMT) and TGF-β signaling for P0 and P2 are shown in the
right-hand panel. p < 0.001 for EMT and TGF-β signaling at P0 and P2. d qRT-PCR analysis of vimentin expression in BC3_A2 MFP tumors and
metastatic subpopulations isolated from lung. Paired t-tests, p= 0.02 for P0 lung, p < 0.001 for P2 lung. Each data point represents one mouse.
Error bars represent SEM of biological replicates. See also Supplementary Fig. 2. e IHC staining was performed on the indicated tissue sections
using an antibody recognizing the human-speciﬁc form of vimentin. Scale bars indicate 100 μm. f Waterfall plot showing expression of EMT
genes in P0 and P2 lung metastases compared with corresponding MFP tumors. p-values are provided in Supplementary Table 1. Samples
from at least three independent mice were included for RNAseq analyses
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of the 230 genes that were most highly upregulated in lung
metastases. ORFs were individually expressed in BC3_A2 cells so
that each cell line expressed a single ORF, cells were then pooled
in groups of 12, and pools were implanted into the MFPs of
recipient mice (n= 10 mice per pool, Fig. 2a). A control plasmid
expressing GFP was included in each pool to gauge intrinsic
metastasis in this TNBC model. Each ORF was associated with a
unique DNA barcode. A reference pellet of pooled cells was snap
frozen to conﬁrm equal representation of each ORF at the time of
tumor implantation. Thirteen weeks was chosen as the study
endpoint because HOXA1, but not GFP-expressing tumors,
metastasized to lung by this time point (Supplementary Fig. 5a).
Thirteen weeks post engraftment, lungs were subjected to BLI
ex vivo (Supplementary Fig. 5a), metastatic lesions were isolated,
and genomic DNA (gDNA) was extracted and used as a template
for qPCR to amplify unique barcode regions associated with each
ORF (Supplementary Fig. 5b). MFP tumors were also isolated and
subjected to these analyses (Fig. 2a). The representation of each
barcoded ORF in the MFP relative to the reference sample was
determined for each pool (Fig. 2b; Supplementary Figs. 5c, d).
Representation in the lung was then normalized to enrichment in
MFPs vs. the reference (Fig. 2b, c). Metastasis drivers segregated
into three groups, including those enriched in both lungs and
MFPs (Fig. 2b, upper right quadrant and Supplementary Fig. 5c),
those enriched exclusively in MFPs (Fig. 2b, lower right quadrant)
and those enriched exclusively in lungs (Fig. 2b, upper left
quadrant and Fig. 2c). Cells expressing GFP were enriched in lung
metastases in some of the pools and the average enrichment
score for GFP in the lung was approximately 5 (Supplementary Fig.
5e). Therefore, we used this as an enrichment score cutoff to
deﬁne a true hit in our screen and identiﬁed 44 genes that were
selectively enriched in lung metastases relative to primary tumors.
These hits were ranked by enrichment score (Fig. 2c and
Supplementary Table 2). Among the top ﬁve hits, CEACAM5 was
the only one whose expression in primary tumors was found to
predict poor survival in breast cancer patients (Supplementary Fig.
6a). Therefore, we further investigated the functional role of
CEACAM5 in breast cancer metastasis.
Conﬁrmation of enhanced CEACAM5 expression in additional
metastatic PDX models
We found that CEACAM5 expression was dynamically regulated as
metastatic subpopulations were serially passaged between lungs
and MFPs in vivo (Fig. 3a), conﬁrming ﬁndings from RNAseq
(Supplementary Table 1 and Supplementary Fig. 6b). Similarly,
CEACAM5 expression was higher in liver (Supplementary Fig. 7a)
and brain (Supplementary Fig. 7b) metastases relative to
corresponding MFP tumors. CEACAM5 protein levels were also
higher in lung metastases relative to MFP tumors (Fig. 3b). The
increase in CEACAM5 expression in metastatic lesions was not
dependent on p53 silencing in this PDX line, as lung metastases
from the isogenic PDX line expressing wild type p5326,30 also
displayed higher expression levels of CEACAM5 (Supplementary
Fig. 7c).
A second set of PDX models of TNBC (PIM001) were evaluated
to determine if the increase in CEACAM5 in metastatic lesions was
a general property of metastasis. PIM001-P was established from
the treatment-naïve primary tumor of a patient with metastatic
TNBC, whereas PIM001-M was established from the dermal
metastasis from the same patient. PIM001-P tumor cells were
engineered to express both CBR-Luc and mCherry and then
engrafted in the MFPs of recipient mice. At time of necropsy, MFP
tumors and lung metastases were isolated. CEACAM5 expression
was increased at both the mRNA-levels (Fig. 3c) and protein-levels
(Fig. 3d) in PIM001-P lung metastases compared with correspond-
ing MFP tumors. Interestingly, CEACAM5 protein levels were
higher in PDX MFP tumors established from the patient’s dermal
metastasis (PIM001-M) compared with the PDX MFP tumors
established from her primary breast tumor (PIM001-P) (Supple-
mentary Fig. 7d). Collectively, these results demonstrate that
elevation of CEACAM5 is a common property of metastases in PDX
models of TNBC.
Fig. 2 High throughput gain-of-function screening in vivo identiﬁes functional drivers of metastasis. a Schematic depicting format used for
gain-of-function (GOF) screen. See also Supplementary Fig. 5. ORF, open reading frame. Ten mice were implanted in each cohort. b Scatter
plot showing relative representation of each ORF in MFP tumors following normalization to the reference (x axis) and in lungs relative to MFP
tumors (y axis). The ΔΔCT method was used for quantiﬁcation of qPCR data. CEACAM5 is shown in red. c Genes enriched in lung metastases
but not MFP tumors [upper left quadrant of panel (b)] were ranked in descending order of enrichment in lung. Dotted line indicates
enrichment score cutoff. See also Supplementary Fig. 5 and Supplementary Table 2
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CEACAM5 expression is inversely correlated with vimentin
expression and phosphorylation of p38
Because expression of CEACAM5 in PDX models was inversely
correlated with expression of vimentin (Figs. 1d, 3a; Supplemen-
tary Figs. 2a and 7a, b), immunohistochemistry (IHC) was
employed to monitor lung metastases and MFP tumors for
relative levels of vimentin and CEACAM5. Protein levels correlated
with mRNA levels in both PDX models (Fig. 3e, f). Vimentin
expression was also inversely correlated with CEACAM5
expression in a panel of breast cancer cell lines (Fig. 3g). The
serine/threonine-speciﬁc protein kinase p38alpha (also known as
MAPK14, hereafter referred to as p38) is phosphorylated during
EMT.31 Interestingly, phosphorylated (active) p38 correlated with
high expression levels of vimentin in MFP tumors, and p38
phosphorylation decreased in lung metastasis where vimentin
levels were low (Fig. 3h). Collectively, these data demonstrate that
CEACAM5 expression is inversely correlated with expression of
EMT markers in lung metastases.
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Ectopic overproduction of CEACAM5 inhibits TGF-β signaling and
expression of EMT markers
Given that CEACAM5 expression inversely correlated with
mesenchymal status, we evaluated whether CEACAM5 had a
direct role in regulating expression of mesenchymal markers.
BC3_A2 cells engineered to overproduce human CEACAM5 or GFP
as a negative control (Supplementary Fig. 8a, b) were examined
for expression of vimentin and CDH2/N-cadherin (mesenchymal
markers) and CDH1/E-cadherin (epithelial marker). Overexpression
of CEACAM5 led to increased expression of CDH1 (Supplementary
Fig. 8c) and decreased expression of CDH2 (Supplementary Fig.
8d) and vimentin (Supplementary Fig. 8e). In addition, over-
production of CEACAM5 reduced and delayed TGF-β mediated
phosphorylation of Smads in BC3_A2 cells (Fig. 4a, c, Supplemen-
tary Fig. 9a) and p38 phosphorylation in both BC3_A2 cells (Fig. 4a,
b, Supplementary Fig. 9a) and MDA-MB-231 cells (Supplementary
Fig. 8f, Supplementary Fig. 9b). Finally, overproduction of
CEACAM5 delayed TGF-β-induced EMT as assessed by E-
cadherin and vimentin expression (Fig. 4d, Supplementary Fig.
9c). These results suggest that CEACAM5 negatively regulates EMT
and identiﬁes a function for CEACAM5 in breast cancer metastasis.
Overproduction of CEACAM5 promotes metastatic outgrowth and
reduces EMT in vivo
EMT is associated with reduced cellular proliferation.19 Thus, the
ability of CEACAM5 to inhibit EMT suggested that it may function
to promote tumor outgrowth at metastatic sites. To test this
hypothesis, BC3_A2 cells engineered to overproduce CEACAM5 or
GFP (control) were injected into the tail veins of recipient mice to
monitor the effects of CEACAM5 overproduction on tumor growth
in the lung. Overexpression of CEACAM5 led to increased tumor
growth in lungs (Fig. 5a and Supplementary Fig. 10a), decreased
expression of vimentin at the protein level (Supplementary Fig.
10b), and decreased phosphorylation of p38 (Fig. 5d, e). Reducing
CEACAM5 levels in BC3_A2 with two different shRNAs (Fig. 5b) had
the opposite effect in that transduced cells grew more slowly in
the lungs than did control cells following tail vein injection (Fig. 5c
and Supplementary Fig. 10c). In addition, CEACAM5 knockdown
resulted in increased lesion number but decreased lesion size
(Supplementary Fig. 10d, e). These results suggest that
CEACAM5 silencing promotes EMT and tumor cell extravasation
while at the same time inhibiting metastatic outgrowth.
To monitor how overproduction of CEACAM5 impacted gene
expression, BC3_A2 cells engineered to overproduce CEACAM5 or
GFP were cultured in vitro or isolated from the lung after tail vein
injection (in vivo). RNA was isolated and subjected to RNAseq.
Differential gene expression analysis was performed, and GSEA
identiﬁed EMT as the only cancer hallmark pathway that was
signiﬁcantly downregulated both in vitro and in vivo by CEACAM5
overproduction (Fig. 5f, Supplementary Fig. 11). This result is
similar to that observed in P0 and P2 lung metastases (Figs. 1c, 5f).
Collectively, these data indicated that upregulation of CEACAM5
expression in metastatic lesions induces MET and enhances the
outgrowth of metastatic tumor cells in secondary sites.
CEACAM5 expression is upregulated in metastatic lesions from
breast cancer patients
Next, CEACAM5 expression was assessed in metastatic lesions and
breast tumor tissue obtained from patients with breast cancer. IHC
staining on a matched tissue set consisting of a primary tumor and
a lung metastasis from a patient with breast cancer (Supplemen-
tary Table 3) revealed higher CEACAM5 levels in the lung
metastasis relative to the primary breast tumor (Fig. 6a and
Supplementary Fig. 12a). To expand these analyses, a tissue
microarray (TMA) consisting of lung metastases from 25 breast
cancer patients (Supplementary Figs. 12b, c and Supplementary
Table 3) was stained for CEACAM5 (Supplementary Fig. 12b), and
staining intensity was assigned a score (Fig. 6b). This scoring
method was also applied to a TMA from the Human Protein Atlas
consisting of human breast tumors stained for CEACAM5.32 The
majority of lung metastases expressed high levels of CEACAM5
(Fig. 6c) compared with breast tumors (Fig. 6d), demonstrating
that CEACAM5 was higher in metastatic lesions compared with
primary breast tumors.
We next assessed the matched tissue set for co-expression of
CEACAM5 and vimentin. Co-staining for CEACAM5 and vimentin
revealed higher levels of CEACAM5 in the lung metastasis relative
to matched breast tumor, and the reverse staining pattern was
observed for vimentin (Fig. 6e, f). In addition, a minor population
of tumor cells exhibited co-staining for both CEACAM5 and
vimentin (Fig. 6f). Those cells staining positive for both proteins
may represent cells in a hybrid EMT/MET state.33 The TMA
consisting of lung metastases from 25 breast cancer patients also
demonstrated an inverse correlation between CEACAM5 and
vimentin staining (Fig. 6g, h; Supplementary Figs. 12a–e). These
results conﬁrmed conclusions made with our PDX models of TNBC
and demonstrated that CEACAM5 expression is inversely corre-
lated with vimentin expression in primary breast tumors and
metastatic lesions. Taken together, these results suggest that
CEACAM5 promotes MET to facilitate tumor outgrowth at
metastatic sites (Supplementary Figure 12a, b).
DISCUSSION
In this study, we utilized PDX models of TNBC and high
throughput gain-of-function (GOF) screens in vivo to identify
drivers of breast cancer metastasis (Supplementary Fig. 13a-b).
Serial passaging of metastatic lesions from lung back into the
MFPs of recipient mice enriched for metastatic potential rather
than for speciﬁc homing of tumor cells to any particular organ. In
addition, serial passaging of metastases enriched for 845 genes
whose expression was signiﬁcantly upregulated in lung lesions
relative to MFP tumors. From this set of upregulated genes, a
custom barcoded library encoding 230 ORFs was generated and
used in a high-throughput pooled-format gain-of-function screen
Fig. 3 CEACAM5 is upregulated in metastases, and its expression is inversely correlated with that of vimentin in PDX models of TNBC. a
Expression of CEACAM5 in MFP tumors and metastatic lesions of mice engrafted with BC3_A2 tumors was determined by qRT-PCR. Paired t-
tests, p < 0.001 for P0 lung, P2 MFP tumor, and P2 lung. Each dot represents an individual mouse. Error bars represent SEM of biological
replicates. See also Supplementary Fig. 7. b MFP tumors and corresponding metastases from mice engrafted with BC3_A2 tumors were
analyzed by IHC using a CEACAM5 antibody. Scale bars indicate 100 μm. c Expression of CEACAM5 in MFP tumors and metastatic lesions of
mice engrafted with PIM001-P tumors was determined by qRT-PCR. Data are presented on a log scale. Paired t-test, p < 0.001. Each dot
represents an individual mouse. Error bars represent SEM of biological replicates. d MFP tumors and corresponding lung metastases from
mice engrafted with PIM001-P tumors were analyzed by IHC using a CEACAM5 antibody. Scale bars indicate 100 μm. e, f IHC of serial tumor
tissue sections from mice engrafted with BC3_A2 (e) or PIM001-P (f) stained with antibodies speciﬁc for CEACAM5 (top panel) or vimentin.
Scale bars indicate 100 μm. g Expression of CEACAM5 (top panel) or vimentin (bottom panel) was determined in a panel of breast cancer cell
lines. Error bars represent SEM of technical triplicates. h IHC was performed to monitor phosphorylated p38 in MFP tumors and lung
metastases of BC3_A2 mice. Scale bars indicate 100 μm
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to evaluate the ability of each gene to drive metastasis in vivo.
CEACAM5 was identiﬁed as a metastatic driver in this screen.
CEACAM5 expression was enhanced in metastases relative to
corresponding mammary fat pad (MFP) tumors, and its expression
was inversely correlated with expression of mesenchymal markers
in both PDX models and patient-derived tissue sections.
Furthermore, CEACAM5 overproduction reduced expression of
mesenchymal markers in breast cancer cells and promoted the
outgrowth of metastatic lesions in the lungs of mice. These results
identify a role for CEACAM5 in regulating the late stages of
metastasis.
We observed that EMT markers were dynamically regulated as
tumors were passaged between the lung and MFP in vivo. EMT
signatures were high in MFP tumors and low in lung metastases.
Metastatic tumor cells are commonly thought to rely on EMT to
escape primary tumors in the initial stages of metastasis by
downregulating intercellular adhesion and proliferation and
acquiring invasive and stem cell-like properties.20 However, the
signiﬁcance of EMT to metastasis has been a long-standing matter
of debate due, in part, to the fact that EMT is often difﬁcult to
observe in real time in vivo in immune-competent mouse models
or in patients because mesenchymal tumor cells that have
undergone EMT resemble ﬁbroblasts in the surrounding host
stroma. This confounding variable was circumvented in our
studies as we employed PDX models, which enable human tumor
cells to be distinguished from mouse stromal cells. Moreover, EMT
is often a transient process, as the up-regulation of EMT programs
in the primary site is associated with growth arrest and allows
tumor cells to escape the primary tumor, but reversion to a more
epithelial state (MET) is necessary for the upregulation of
proliferation to establish macrometastases.19,21,22 Studies have
shown that the pre-metastatic niche can also inﬂuence whether
Fig. 4 CEACAM5 overproduction downregulates expression of mesenchymal markers and impairs TGF-β signaling and impairs TGF-β
signaling. a BC3_A2 cells engineered to overproduce CEACAM5 or GFP were cultured in the presence or absence of 1 ng/ml TGF-β for the
indicated time periods. Cellular lysates were subjected to Western blotting for the indicated proteins. b, c Histogram shows the fold change
(log scale) in phosphorylation status of p38 (b) or Smad2/3 (c) compared with that at time point 0 for cells expressing GFP. Error bars represent
SEM of at least three independent experiments. d BC3_A2 cells expressing GFP or CEACAM5 were cultured in the presence or absence of 1 ng/
ml TGF-β for the indicated time periods. Cellular lysates were subjected to Western blotting for the indicated proteins. All results are
representative of at least three independent experiments. See also Supplementary Figs. 8 and 9
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Fig. 5 Expression of CEACAM5 promotes growth of lung metastases. a BC3_A2 cells overproducing CEACAM5 or GFP were injected into the
tail veins of mice. BLI was used to quantify photon ﬂux in the lungs of mice at the indicated time points. Paired t-test, p= 0.03. Error bars
represent SEM of biological replicates (n= 5 mice per group). b BC3_A2 cells expressing control shRNA (shLuc) or two different shRNAs (#3
and #5) speciﬁc for CEACAM5 were subjected to qRT-PCR to monitor CEACAM5 expression. Error bars represent SEM of technical triplicates.
See also Supplementary Fig. 10. c BC3_A2 cells expressing shLuc or two different CEACAM5 shRNAs were injected into the tail veins of mice.
BLI was used to quantify photon ﬂux in the lungs of mice at the indicated time points. Paired t-tests, p= 0.01 for sh#3 and p < 0.001 for sh#5.
Data were normalized to the initial time point and are presented on a log scale. Error bars represent SEM of biological replicates (n= 5 mice
per group). d BC3_A2 cells overproducing CEACAM5 were injected into the tail veins of mice, and lungs were isolated and subjected to IHC
with the indicated antibodies. Scale bars indicate 100 μm. e Cells staining positive for CEACAM5, vimentin, or p-p38 in the tissue sections
represented in panel d were quantitated using the Vectra 3.0 automated imaging system. Paired t-tests, p= 0.0008 for CEACAM5, p= 0.03 for
vimentin, and p= 0.03 for p-p38. Error bars represent SEM of at least three independent biological replicates. f RNA isolated from BC3_A2 cells
overproducing CEACAM5 or GFP and cultured either in vitro or isolated from the lung after tail vein injection (in vivo, a, d) was subjected to
GSEA pathway analysis (left two columns). The top 5 down-regulated (blue) and top 5 up-regulated (red) processes are shown. Boxes indicate
FDR <0.1 for statistical signiﬁcance. NES (normalized enrichment score). Signiﬁcance of these pathways in P0 and P2 MFP tumors vs.
corresponding lung metastases is shown for comparison (right two columns). Data are represented of biological triplicates. See also
Supplementary Fig. 11
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tumor cells will efﬁciently seed and proliferate there,34 but what
initiates the switch to MET at the metastatic site has not been
determined. Our data demonstrate that CEACAM5 has a role in
this process and suggest that perturbation of MET programs may
be a therapeutic strategy to restrain tumor outgrowth at the
metastatic site.
Although MET programs may retard the growth of metastatic
lesions, inhibition of MET in metastatic tumor cells may in turn
lead to the upregulation of EMT-associated tumor cell migration,
consequently resulting in secondary metastases. Thus, one
limitation of this study is that clinical application of these ﬁndings
may be a palliative, rather than curative, therapeutic strategy.
Additionally, the mechanisms by which MET promotes lung
metastasis have not been fully elucidated. Upregulation of MET
may inﬂuence multiple steps in the metastatic cascade including
increased cell survival in circulation, increased adhesion to blood
vessels in secondary sites, or increased proliferation during
metastatic colonization. Finally, it is important to note that these
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studies were conducted in immune-compromised mice, and thus,
the contribution of the immune system to metastasis cannot be
fully explored in this system. However, elevated expression of
CEACAM5 was conﬁrmed in metastatic lesions obtained directly
from cancer patients, thus conﬁrming the clinical relevance of our
ﬁndings.
CEACAM5 is not expressed on most normal adult tissues
including the breast; its expression is restricted to the apical
surface of the gastrointestinal tract.35 High CEACAM5 expression
in breast tumors correlates with reduced patient survival.36–38
Additionally, CEACAM5 is secreted into the blood of breast cancer
patients, and elevated serum levels indicate progression to
metastasis.39 CEACAM5 is also a well-recognized tumor and serum
biomarker for the progression of colorectal and pancreatic
cancers.40,41 We demonstrated that CEACAM5 expression is
elevated in metastatic breast cancer cells compared with the
corresponding primary breast tumors in PDX models of TNBC and
in tissue sections obtained directly from breast cancer patients. In
preclinical models, anti-CEACAM5 neutralizing antibodies have to
been shown to affect cell adhesion, migration, and invasion
in vitro, and pre-incubation of tumor cells with these antibodies
resulted in decreased metastasis of tumor cells following
intrasplenic injection.42 Collectively, these results suggest that
CEACAM5 may serve as a tumor and serum biomarker for
metastatic progression and may also be a viable therapeutic
target.
Attempts to target CEACAM5 with anticancer therapeutic
approaches have included the development and clinical imple-
mentation of vaccines, immunotherapies, and antibodies.43
However, the ability of these agents to target tumors and
suppress their growth is limited, and relatively few drugs that
directly target CEACAM5 have been developed. Accordingly, the
most effective treatments are based on stimulation of immune
responses against CEACAM5.43 Our results suggest that the
development of novel therapeutic agents directly targeting
CEACAM5 could be effective in inhibiting tumor outgrowth in
the metastatic setting. However, one concern is that this could
also promote migratory properties of tumor cells through
expression of EMT markers thereby favoring mesenchymal
(migratory)-like properties and secondary metastatic seeding
events. Our ﬁnding that CEACAM5 can inhibit p38 activity and
promote the growth of metastatic lesions agrees with previous
studies showing that pharmacologic inhibition of p38 promotes
the outgrowth of micrometastatic tumor cells, likely through
induction of MET.44 Thus, metastatic stage should be carefully
considered before clinical application of pharmacologic agents
targeting these pathways.
Despite remarkable recent advances in pharmacologic devel-
opment, outcomes for patients with metastatic breast cancer
remain poor. Therefore, there is a clear need to elucidate the
molecular mechanisms governing the progression of established
metastatic tumors. Identifying molecules that promote macro-
metastasis, such as CEACAM5, is expected to lead to the
development of new therapeutic targets and the application of
existing therapies for patients with advanced metastatic disease.
METHODS
Study approval
Similar to our previous studies,28 this study was carried out in accordance
with the sanctions in the Guide for the Care and Use of Laboratory Animals
from the National Institutes of Health (NIH) Institutional Animal Care and
use Committee (IACUC). The IACUC protocol was approved by the
Committee on the Ethics of Animal Experiments of Washington University
and the IACUC at MD Anderson Cancer Center. Mice were humanely
euthanized as dictated by the Association for Assessment and Accredita-
tion of Laboratory Animal Care International and IACUC euthanasia
endpoints when they became moribund or when they reached deﬁned
study end points. Animals were euthanized as dictated by the Association
for Assessment and Accreditation of Laboratory Animal Care International
and IACUC euthanasia end points. Informed consent was obtained from all
living patients from whom data was included in this study.
Establishment of PDX models
PDX models were established according to published methods.28,45 Brieﬂy,
GFP-labeled human stromal ﬁbroblasts were irradiated with 400 Rads and
mixed with an equal number of non-irradiated ﬁbroblasts (2.5 × 105
irradiated cells and 2.5 × 105 non-irradiated cells). Fibroblasts were then
mixed with 1 × 106 BC3_A2 tumor cells and 1/3 volume Matrigel. This
mixture was injected into the fourth mammary fat pads of 4 to 5-week-old
female nonobese diabetic/severe combined immunodeﬁciency (NOD/
SCID) mice (NOD.CB17-Prkdcscid/NcrCrl, Charles River, NCI Colony). PIM001-
P and PIM001-M tumor cells were not mixed with ﬁbroblasts prior to
implantation. Tumors were resected in a survival surgery when they
reached approximately 1 cm in diameter. Animals were euthanized when
they became moribund or a maximum of 30 weeks post-tumor-
implantation.
Serial passaging of tumors in vivo
Metastases were isolated at animal necropsy using bioluminescence-
guided macro-dissection. Tissues were digested to single cells and
organoids in collagenase and hyaluronidase for 4 h at 37 oC on a rotator.
Tumor cells were washed in DMEM/F12 with 5% bovine calf serum, and red
blood cells were lysed for 5 min at room temperature (RBC lysis buffer;
Sigma-Aldrich R7757). Cells were passed through a 70 μm ﬁlter and
counted using a ﬂuorescence-coupled microscope (only the mCherry-
positive cells were counted). A maximum of 1 × 106 mCherry-positive
tumor cells were then implanted into the fourth mammary fat pads of
recipient mice, along with irradiated and non-irradiated human stromal
ﬁbroblasts and 1/3 volume Matrigel.
Analysis of qPCR data for in vivo screen
Barcode quantiﬁcation was carried out using the DDCt method.46 First,
barcode quantiﬁcation cycle (Cq) values were normalized to total DNA with
the Cq value for DNA reference probe. Next, tumor sample barcode values
were converted into a fold change relative to the respective pooled
reference sample. ΔΔCt of the lung vs. the mammary was also calculated
for each matched pair, and samples with three or more matched pairs
were averaged to rank hits. Samples with fewer than three data points
Fig. 6 CEACAM5 protein levels are elevated in metastatic lesions of breast cancer patients and are inversely correlated with expression of
vimentin. a The primary tumor and corresponding lung metastasis from a patient with breast cancer were subjected to IHC to monitor
CEACAM5 levels. Scale bars indicate 100 μm. b A tumor tissue microarray (TMA) consisting of lung metastases from 25 breast cancer patients
was subjected to IHC with a CEACAM5-speciﬁc antibody, and staining intensity was scored. Representative images are shown. Scale bars
indicate 100 μm. c The scoring system in b was applied to the TMA consisting of lung metastases from 25 breast cancer patients to assess
relative CEACAM5 levels. d The scoring system in b was applied to a TMA from the Human Protein Atlas consisting of 25 primary breast
tumors to assess relative CEACAM5 levels. e The primary tumor and corresponding lung metastasis from a patient with breast cancer (from a)
were co-stained for CEACAM5 and vimentin and analyzed by immunoﬂuorescence microscopy. Scale bars indicate 100 μm. f Cells staining
positive for CEACAM5, vimentin, or both in the tissue sections represented in e were quantitated using the Vectra 3.0 automated imaging
system. g The TMA consisting of lung metastases from 25 breast cancer patients was co-stained for CEACAM5 and vimentin and analyzed by
immunoﬂuorescence microscopy. Representative images are shown. Scale bars indicate 100 μm. h Cells staining positive for CEACAM5,
vimentin, or both in the tissue sections shown in g were quantitated using the Vectra 3.0 automated imaging system. See also Supplementary
Fig. 12
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were not considered for analysis. All genes with an average depletion of at
least two-fold in the mammary relative to the reference pool were
considered as putative metastatic drivers (hits).
RNAseq and data analysis
Tumors were harvested in a survival surgery when they reached 1 cm and
were immediately snap frozen in liquid nitrogen. Metastatic lesions were
harvested by bioluminescence-guided macro-dissection and immediately
snap frozen in liquid nitrogen. Mice with the largest metastatic lesions
were selected for RNAseq. Similar to our previous studies,28 tumors were
snap frozen to preserve RNA integrity and avoid experimental manipula-
tions that could lead to alterations in gene expression. Tumors were stored
at −80 °C, thawed on ice in Trizol, and homogenized with a pedestal
homogenizer. Total RNA was extracted with chloroform followed by
puriﬁcation using the RNEASY kit (Qiagen, Venlo, The Netherlands; 74104).
Total RNA was treated with DNase (TURBO DNase, Life Technologies,
Carlsbad, CA, USA; AM2238) followed by column puriﬁcation (RNA Clean &
Concentrator-5, Zymo Research, Irvine, CA, USA; R1015). mRNA was
isolated by poly-A selection. RNA Integrity Number (RIN) was assessed on a
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). RNAseq libraries
were prepared and sequencing was performed by the Genome
Technology Access Center (Washington University, St. Louis, MO, USA).
RNAseq reads were ﬁrst mapped to the mouse reference genome (UCSC
mm10) using Tophat2 (v2.0.14) and Bowtie2 (v2.2.2), allowing a maximum
of two mismatches per 75 bp read end. The unmapped reads were then
aligned to the human genome (UCSC hg19) using the same tool and
parameters. Gene-level read counts were quantiﬁed using HTseq (http://
www.huber.embl.de/users/anders/HTSeq/doc/overview.html). Normaliza-
tion and differential expression analyses for gene/isoform expression were
performed using DESeq2.47 The log2 fold-change 1.5 and adjusted p-value
cutoff <0.05 were used to identify differentially expressed genes. log10 p-
values from the differential analysis were used to build the rank ﬁle for pre-
ranked GSEA against the Cancer Hallmark pathways.48,49 Numbers of mice
included in each analysis were as follows: P0 MFP tumors, n= 3; P0 lung
metastases n= 4; P2 MFP tumors, n= 3; P2 lung metastases, n= 3; BC3_A2
cells expressing GFP and injected into tail veins, n= 3; BC3_A2 cells
expressing CEACAM5 and injected into tail veins, n= 3.
Statistics
Photon ﬂuxes were normalized to the time of study end point as described
previously.28 Wilcoxon rank sum tests were used to evaluate the mean
differences in photon ﬂux in each organ due to relatively small sample size
in most groups. Hierarchical clustering of RNAseq data was performed
using Euclidean distance and complete linkage. PCA plots and heat maps,
and statistical analyses were performed using R (http://www.r-project.org/).
Kaplan–Meier survival analysis
Similar to our previous studies,28 the univariate Cox proportional hazard
model was used to assess the correlation of gene expression with patient
overall survival, and the log-rank p-value was reported. The dataset from
The Cancer Genome Atlas (TCGA)50 was used for determining overall
survival of breast cancer patients. Log-rank tests were used to estimate the
p-values between high and low expression groups using the top and
bottom 10% as the cutoff for grouping.
Data availability
RNAseq data are publically available at Sequence Read Archive (SRA),
accession numbers SRP133840.
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